Literature DB >> 29750006

A Novel Integrated Cognitive-Behavioral Therapy for Anxiety and Medication Adherence Among Persons Living With HIV/AIDS.

Charles P Brandt1, Daniel J Paulus2, Monica Garza, Chad Lemaire3, Peter J Norton4, Michael J Zvolensky5.   

Abstract

Persons living with HIV/AIDS (PLHIV) are able to live full lifespans after infection, however, rates of anxiety disorders among this population are elevated compared to national samples. Importantly, these anxiety symptoms and disorders have a negative effect on medication adherence, quality of life and other psychological disorders, such as depression. In order to reduce the impact of anxiety among PLHIV, a six-session transdiagnostic CBT-based treatment manual for anxiety among PLHIV named the HIV/Anxiety Management-Reduction Treatment (HAMRT) was developed and implemented. The current manuscript discusses the content of this manual as well as results from three cases examining the impact of HAMRT. Results indicated that HAMRT was effective in reducing symptoms of anxiety, anxiety sensitivity, depression, and negative affect among our sample. Additionally, results indicated that HAMRT was effective in increasing HIV medication adherence as well as quality of life. Results are discussed in terms of the potential utility of an anxiety-reduction therapy program aimed at increasing medication adherence among PLHIV.

Entities:  

Keywords:  HIV; anxiety; anxiety sensitivity; medication adherence; negative affect

Year:  2017        PMID: 29750006      PMCID: PMC5937542          DOI: 10.1016/j.cbpra.2017.01.007

Source DB:  PubMed          Journal:  Cogn Behav Pract        ISSN: 1077-7229


  46 in total

1.  Exploration of health anxiety among individuals with diabetes: prevalence and implications.

Authors:  Jennifer A Janzen Claude; Heather D Hadjistavropoulos; Lindsay Friesen
Journal:  J Health Psychol       Date:  2013-01-24

2.  Structural relationships among dimensions of the DSM-IV anxiety and mood disorders and dimensions of negative affect, positive affect, and autonomic arousal.

Authors:  T A Brown; B F Chorpita; D H Barlow
Journal:  J Abnorm Psychol       Date:  1998-05

3.  Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART).

Authors:  Shilpa Viswanathan; Roger Detels; Shruti H Mehta; Bernard J C Macatangay; Gregory D Kirk; Lisa P Jacobson
Journal:  AIDS Behav       Date:  2015-04

4.  Risk factors and symptoms associated with pain in HIV-infected adults.

Authors:  Bradley E Aouizerat; Christine A Miaskowski; Caryl Gay; Carmen J Portillo; Traci Coggins; Harvey Davis; Clive R Pullinger; Kathryn A Lee
Journal:  J Assoc Nurses AIDS Care       Date:  2010-01-29       Impact factor: 1.354

5.  Beyond Negative Affectivity: A Hierarchical Model of Global and Transdiagnostic Vulnerabilities for Emotional Disorders.

Authors:  Daniel J Paulus; Alexander M Talkovsky; Luke F Heggeness; Peter J Norton
Journal:  Cogn Behav Ther       Date:  2015-03-03

Review 6.  Cardiovascular complications in HIV management: past, present, and future.

Authors:  Judith A Aberg
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

7.  A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals.

Authors:  Steven A Safren; Conall O'Cleirigh; Judy Y Tan; Sudha R Raminani; Laura C Reilly; Michael W Otto; Kenneth H Mayer
Journal:  Health Psychol       Date:  2009-01       Impact factor: 4.267

8.  Functional impairment and health care utilization among HIV-infected men who have sex with men: the relationship with depression and post-traumatic stress.

Authors:  Conall O'Cleirigh; Margie Skeer; Kenneth H Mayer; Steven A Safren
Journal:  J Behav Med       Date:  2009-06-13

9.  Validation of the World Health Organization quality of life instrument in patients with HIV infection.

Authors:  C T Fang; P C Hsiung; C F Yu; M Y Chen; J D Wang
Journal:  Qual Life Res       Date:  2002-12       Impact factor: 3.440

10.  Management of common adverse effects in the era of highly active antiretroviral therapy in south east Ethiopia.

Authors:  Sadikalmahdi Hussen Abdella; Nasir Tajure Wabe; Elias Ali Yesuf
Journal:  N Am J Med Sci       Date:  2011-11
View more
  6 in total

1.  Trajectory of change in anxiety sensitivity in relation to anxiety, depression, and quality of life among persons living with HIV/AIDS following transdiagnostic cognitive-behavioral therapy.

Authors:  Daniel J Paulus; Charles P Brandt; Chad Lemaire; Michael J Zvolensky
Journal:  Cogn Behav Ther       Date:  2019-07-02

2.  "If They Give Their Mind to HIV, They Don't Last as Long": An Explanatory Model of HIV Infection in a Limited-Resource Setting Informs Person-Centered Care.

Authors:  Samantha Stonbraker; Gabriella Sanabria; Silvia Cunto-Amesty; Carmela Alcántara; Ana F Abraído-Lanza; Tawandra Rowell-Cunsolo; Mina Halpern; Suzanne Bakken; Rebecca Schnall; Maureen George
Journal:  Glob Qual Nurs Res       Date:  2022-06-13

3.  Medication adherence to antiretroviral therapy among newly treated people living with HIV.

Authors:  Yang Yu; Dan Luo; Xi Chen; Zhulin Huang; Min Wang; Shuiyuan Xiao
Journal:  BMC Public Health       Date:  2018-07-04       Impact factor: 3.295

4.  Factors associated with current and severe pain among people living with HIV: results from a statewide sample.

Authors:  Verlin Joseph; Abenaa Jones; Shantrel Canidate; Zachary Mannes; Huiyin Lu; Nichole Ennis; Gladys Ibanez; Charurut Somboonwit; Robert Cook
Journal:  BMC Public Health       Date:  2020-09-18       Impact factor: 3.295

5.  Symptoms of generalized anxiety disorder as a risk factor for substance use among adults living with HIV.

Authors:  Zachary L Mannes; Eugene M Dunne; Erin G Ferguson; Robert L Cook; Nicole Ennis
Journal:  AIDS Care       Date:  2020-08-24

6.  Cognitive ageing is premature among a community sample of optimally treated people living with HIV.

Authors:  H L Aung; M Bloch; T Vincent; D Quan; A Jayewardene; Z Liu; T M Gates; B Brew; L Mao; L A Cysique
Journal:  HIV Med       Date:  2020-10-21       Impact factor: 3.180

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.